Limits...
Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.

Rameh V, Kossaify A - Biomark Insights (2016)

Bottom Line: Pulmonary hypertension is a severe and debilitating disease with no definite cure, and the domain of targeted therapies is a promising field for better management of this severe condition.The disease comprises pulmonary arterial remodeling, hypoxia, endothelial dysfunction, and inflammation, with subsequent organ damage including right heart and liver dysfunction.Biomarkers have a valuable role at different levels of the disease, from diagnosis to risk assessment and management, in order to decrease the burden of the disease in terms of both morbidity and mortality.

View Article: PubMed Central - PubMed

Affiliation: Echocardiography Unit, Cardiology division, University Hospital Notre Dame des Secours, Byblos, Lebanon.

ABSTRACT
Pulmonary hypertension is a severe and debilitating disease with no definite cure, and the domain of targeted therapies is a promising field for better management of this severe condition. The disease comprises pulmonary arterial remodeling, hypoxia, endothelial dysfunction, and inflammation, with subsequent organ damage including right heart and liver dysfunction. Biomarkers have a valuable role at different levels of the disease, from diagnosis to risk assessment and management, in order to decrease the burden of the disease in terms of both morbidity and mortality.

No MeSH data available.


Related in: MedlinePlus

Schematic figure representing the etiologies of PH.Abbreviations: PH, pulmonary hypertension; PAH, pulmonary arterial hypertension related to idiopathic, heritable, drug-induced, or associated PH; LHD, left heart disease; CTED, chronic thromboembolic disease; Id-MF, idiopathic, multifactorial etiology.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4920202&req=5

f1-bmi-11-2016-085: Schematic figure representing the etiologies of PH.Abbreviations: PH, pulmonary hypertension; PAH, pulmonary arterial hypertension related to idiopathic, heritable, drug-induced, or associated PH; LHD, left heart disease; CTED, chronic thromboembolic disease; Id-MF, idiopathic, multifactorial etiology.

Mentions: PH is classified into five groups: group 1, PAH (comprising idiopathic, heritable, drug-induced, associated PAH, and persistent PH of the newborn); group 2, PH consecutive to left heart disease; group 3, PH consecutive to lung diseases and/or hypoxia; group 4, PH consecutive to chronic thromboembolic disease; and group 5, PH with unclear and/or multifactorial mechanisms (Fig. 1).9 According to the REVEAL study,10 variables independently associated with increased mortality in PH include the following: high pulmonary vascular resistance (>32 Wood units), high mean right atrial pressure (>20 mmHg), resting systolic blood pressure <110 mmHg, heart rate >92 bpm, right ventricular dysfunction, portal hypertension, men >60 years old, family history of PH, presence of renal insufficiency, PH associated with connective tissue disease, New York Heart Association (NYHA) functional class >2, brain natriuretic peptide (BNP) >180 pg/mL, percent predicted carbon monoxide diffusing capacity <32%, and presence of pericardial effusion (Table 1).


Role of Biomarkers in the Diagnosis, Risk Assessment, and Management of Pulmonary Hypertension.

Rameh V, Kossaify A - Biomark Insights (2016)

Schematic figure representing the etiologies of PH.Abbreviations: PH, pulmonary hypertension; PAH, pulmonary arterial hypertension related to idiopathic, heritable, drug-induced, or associated PH; LHD, left heart disease; CTED, chronic thromboembolic disease; Id-MF, idiopathic, multifactorial etiology.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4920202&req=5

f1-bmi-11-2016-085: Schematic figure representing the etiologies of PH.Abbreviations: PH, pulmonary hypertension; PAH, pulmonary arterial hypertension related to idiopathic, heritable, drug-induced, or associated PH; LHD, left heart disease; CTED, chronic thromboembolic disease; Id-MF, idiopathic, multifactorial etiology.
Mentions: PH is classified into five groups: group 1, PAH (comprising idiopathic, heritable, drug-induced, associated PAH, and persistent PH of the newborn); group 2, PH consecutive to left heart disease; group 3, PH consecutive to lung diseases and/or hypoxia; group 4, PH consecutive to chronic thromboembolic disease; and group 5, PH with unclear and/or multifactorial mechanisms (Fig. 1).9 According to the REVEAL study,10 variables independently associated with increased mortality in PH include the following: high pulmonary vascular resistance (>32 Wood units), high mean right atrial pressure (>20 mmHg), resting systolic blood pressure <110 mmHg, heart rate >92 bpm, right ventricular dysfunction, portal hypertension, men >60 years old, family history of PH, presence of renal insufficiency, PH associated with connective tissue disease, New York Heart Association (NYHA) functional class >2, brain natriuretic peptide (BNP) >180 pg/mL, percent predicted carbon monoxide diffusing capacity <32%, and presence of pericardial effusion (Table 1).

Bottom Line: Pulmonary hypertension is a severe and debilitating disease with no definite cure, and the domain of targeted therapies is a promising field for better management of this severe condition.The disease comprises pulmonary arterial remodeling, hypoxia, endothelial dysfunction, and inflammation, with subsequent organ damage including right heart and liver dysfunction.Biomarkers have a valuable role at different levels of the disease, from diagnosis to risk assessment and management, in order to decrease the burden of the disease in terms of both morbidity and mortality.

View Article: PubMed Central - PubMed

Affiliation: Echocardiography Unit, Cardiology division, University Hospital Notre Dame des Secours, Byblos, Lebanon.

ABSTRACT
Pulmonary hypertension is a severe and debilitating disease with no definite cure, and the domain of targeted therapies is a promising field for better management of this severe condition. The disease comprises pulmonary arterial remodeling, hypoxia, endothelial dysfunction, and inflammation, with subsequent organ damage including right heart and liver dysfunction. Biomarkers have a valuable role at different levels of the disease, from diagnosis to risk assessment and management, in order to decrease the burden of the disease in terms of both morbidity and mortality.

No MeSH data available.


Related in: MedlinePlus